MedWatch

MPI test to give old chemotherapy a new lease on life

The Danish company Medical Prognosis Institute has developed a biomarker test that should revitalize a common chemotherapy drug against breast cancer. CEO Peter Buhl Jensen calls it ”the biomarker of the future.”

Foto: Krabbe Lars, Jyllands-Posten

The Danish diagnostics company Medical Prognosis Institute (MPI) has presented promising results for a new type of biomarker test, able to predict the efficacy of the chemotherapy epirubicin, one the of most used drugs in breast cancer treatment.

CEO Peter Buhl Jensen has high expectations for the test which is to be used with a new alternative edition of the chemotherapy drug.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier